139 related articles for article (PubMed ID: 21740304)
1. B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy.
Kim SJ; Won JH
Leuk Lymphoma; 2012 Jan; 53(1):19-25. PubMed ID: 21740304
[TBL] [Abstract][Full Text] [Related]
2. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.
Alousi AM; Uberti J; Ratanatharathorn V
Leuk Lymphoma; 2010 Mar; 51(3):376-89. PubMed ID: 20141428
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA; Bazarbachi A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
[TBL] [Abstract][Full Text] [Related]
4. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
5. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.
van Dorp S; Pietersma F; Wölfl M; Verdonck LF; Petersen EJ; Lokhorst HM; Martens E; Theobald M; van Baarle D; Meijer E; Kuball J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):671-8. PubMed ID: 19450751
[TBL] [Abstract][Full Text] [Related]
6. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients.
Crocchiolo R; Castagna L; El-Cheikh J; Helvig A; Fürst S; Faucher C; Vazquez A; Granata A; Coso D; Bouabdallah R; Blaise D
Exp Hematol; 2011 Sep; 39(9):892-6. PubMed ID: 21703987
[TBL] [Abstract][Full Text] [Related]
7. B cells in chronic graft-versus-host disease.
McManigle W; Youssef A; Sarantopoulos S
Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450
[TBL] [Abstract][Full Text] [Related]
8. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
Sarantopoulos S; Stevenson KE; Kim HT; Washel WS; Bhuiya NS; Cutler CS; Alyea EP; Ho VT; Soiffer RJ; Antin JH; Ritz J
Blood; 2011 Feb; 117(7):2275-83. PubMed ID: 21097674
[TBL] [Abstract][Full Text] [Related]
9. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
[TBL] [Abstract][Full Text] [Related]
10. The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.
van Dorp S; Resemann H; te Boome L; Pietersma F; van Baarle D; Gmelig-Meyling F; de Weger R; Petersen E; Minnema M; Lokhorst H; Ebeling S; Beijn SJ; Knol EF; van Dijk M; Meijer E; Kuball J
Haematologica; 2011 Sep; 96(9):1380-4. PubMed ID: 21546493
[TBL] [Abstract][Full Text] [Related]
11. B-cell involvement in chronic graft-versus-host disease.
Kapur R; Ebeling S; Hagenbeek A
Haematologica; 2008 Nov; 93(11):1702-11. PubMed ID: 18728020
[TBL] [Abstract][Full Text] [Related]
12. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT.
Dominietto A; Tedone E; Soracco M; Bruno B; Raiola AM; Van Lint MT; Geroldi S; Lamparelli T; Galano B; Gualandi F; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 2012 Jan; 47(1):101-6. PubMed ID: 21460867
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in immunologic glomerular diseases.
Ejaz AA; Asmar A; Alsabbagh MM; Ahsan N
MAbs; 2012; 4(2):198-207. PubMed ID: 22377738
[TBL] [Abstract][Full Text] [Related]
14. B cells in chronic graft-versus-host disease.
Sarantopoulos S; Blazar BR; Cutler C; Ritz J
Biol Blood Marrow Transplant; 2015 Jan; 21(1):16-23. PubMed ID: 25452031
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for prevention and treatment of graft-versus-host disease.
Kharfan-Dabaja MA; Cutler CS
Int J Hematol; 2011 May; 93(5):578-585. PubMed ID: 21547615
[TBL] [Abstract][Full Text] [Related]
16. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
Simpson D
BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
[TBL] [Abstract][Full Text] [Related]
17. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
Cutler C; Kim HT; Bindra B; Sarantopoulos S; Ho VT; Chen YB; Rosenblatt J; McDonough S; Watanaboonyongcharoen P; Armand P; Koreth J; Glotzbecker B; Alyea E; Blazar BR; Soiffer RJ; Ritz J; Antin JH
Blood; 2013 Aug; 122(8):1510-7. PubMed ID: 23861248
[TBL] [Abstract][Full Text] [Related]
18. The role of B cells in the pathogenesis of graft-versus-host disease.
Shimabukuro-Vornhagen A; Hallek MJ; Storb RF; von Bergwelt-Baildon MS
Blood; 2009 Dec; 114(24):4919-27. PubMed ID: 19749094
[TBL] [Abstract][Full Text] [Related]
19. Management of acute graft versus host disease (GvHD).
Bacigalupo A; Palandri F
Hematol J; 2004; 5(3):189-96. PubMed ID: 15167903
[TBL] [Abstract][Full Text] [Related]
20. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
